



**Press Release – April 2021**

## **Delta 4 Announces Closing of Multi-million Series A Financing Round**

- Company to Expand Focus Beyond Renal Diseases and COVID-19
- Compounds Identified in Current Discovery Programs Ready for Clinical Development

**Vienna, Europe (April 7, 2021)** – Delta 4, a digital drug discovery company focusing on the identification of new indications for existing drug compounds, today announced that it successfully closed a multi-million Euro Series A financing round. The additional funding was provided by a major European Family Office investing in the life sciences, technology and other industries. Delta 4 will use the funding to accelerate the growth of its business. Further details on this financing round were not provided.

In 2020, the Company announced that it has identified promising drug compounds for the treatment of a rare kidney disease and COVID-19. In recent months, these compounds were readied for Phase 2 clinical development. Delta 4 will now expand its clinical scope and initiate discovery and development programs in additional indications.

“We are excited that the milestones achieved in our current discovery and development programs attracted an experienced investor in our field who will join our investor base”, said Kurt Herpel, CEO, Delta 4. “In recent months, Delta 4 has highlighted its capabilities as a drug discovery engine able to generate a short list of drug candidates just months after applying our proprietary drug discovery platform to a targeted disease. Overall, it took us less than a year from the start of the discovery program to have the most promising candidate validated in vivo and readied for clinical development. Following this financing round, we will swiftly move into additional disease areas to consistently add to our pipeline of drug compounds that we can partner with the pharmaceutical industry.”

### **About Delta 4’s Drug Discovery Platform**

Delta 4’s drug discovery platform was successfully applied in contract research for global pharma and biotechnology companies. The platform integrates in-silico drug discovery and big

data analysis with extensive expertise in molecular biology and clinical development. Due to its unique technology, Delta 4 delivers not only drug candidates but also a mechanistic hypothesis about the underlying mode of action, significantly increasing their value for pharmaceutical development.

## **About Delta 4**

Delta 4 is a drug discovery and development company, combining in-silico drug discovery and big data analysis with extensive expertise in molecular biology and clinical development to a powerful proprietary drug discovery platform. This platform generates promising drug candidates annotated with biological and medical information, resulting in a fast track to establish a clinical proof of concept.

The Company focuses on the discovery of novel indications for approved drugs (drug repositioning). In its first therapeutic area, focal segmental glomerulosclerosis (FSGS), a devastating renal disease with high and urgent medical need, Delta 4 has identified and pre-clinically validated promising drug candidates that are currently prepared for clinical proof-of-concept. In 2020, the Company applied its drug discovery platform to additional indications. As a result, Delta 4 has readied a potential COVID-19 therapy for Phase 1 development and filed four patent applications for compounds in two indications.

Delta 4 was founded in 2019. The Company is based in Vienna, Austria.

### **Contact:**

Kurt Herpel, CEO

Delta 4 GmbH

Gersthofer Strasse 29 – 31

1180 Vienna

Austria

[office@delta4.ai](mailto:office@delta4.ai)

+41 79 874 13 22